(NASDAQ: AVBP) Arrivent Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Arrivent Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast AVBP's revenue for 2026 to be $393,518,757, with the lowest AVBP revenue forecast at $393,518,757, and the highest AVBP revenue forecast at $393,518,757. On average, 3 Wall Street analysts forecast AVBP's revenue for 2027 to be $2,395,028,178, with the lowest AVBP revenue forecast at $1,712,009,437, and the highest AVBP revenue forecast at $3,108,798,179.
In 2028, AVBP is forecast to generate $7,117,821,225 in revenue, with the lowest revenue forecast at $5,440,295,390 and the highest revenue forecast at $9,675,693,144.